Beltrani V S
Department of Dermatology, College of Physicians & Surgeons, Columbia University, New York, NY, USA.
J Allergy Clin Immunol. 1999 Sep;104(3 Pt 2):S87-98. doi: 10.1016/s0091-6749(99)70050-3.
Updating our clinical concept of atopic dermatitis (AD) evolves from the better understanding of all the immunologic aberrations expressed by the polygenic combinations and permutations associated with the atopic diathesis. Recognizing the immunopathologic features of AD readily underscores that AD without "atopy" is an oxymoron. Appreciating "pruritus" as the impetus to scratch, which isomorphically gives rise to the "eczema," shifts the goal of management from suppressing inflammation to avoiding the triggers of pruritus. Recognizing the full spectrum of dermatologic findings in AD endorses the preferred label as a dermatitis, rather than the inferred restrictive label, atopic eczema. As our knowledge of immunology evolves, our criteria for the diagnosis and management of the atopic diathesis are sure to change.
更新我们对特应性皮炎(AD)的临床概念,源于对与特应性素质相关的多基因组合和排列所表现出的所有免疫异常有了更深入的理解。认识到AD的免疫病理特征很容易就突出表明,没有“特应性”的AD是一种矛盾修辞法。将“瘙痒”视为搔抓的诱因,搔抓同形地引发“湿疹”,这将治疗目标从抑制炎症转变为避免瘙痒的触发因素。认识到AD中皮肤病学表现的全貌,支持将首选名称定为皮炎,而不是推断性的限制性名称——特应性湿疹。随着我们对免疫学的认识不断发展,我们对特应性素质的诊断和治疗标准肯定会发生变化。